UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37372 Collegium Pharmaceutical, Inc. (Exact name of registrant as specified in its charter) Virginia (State or other jurisdiction of incorporation or o ...

Exhibit 99.1 Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results – Generated Record Quarterly and Full-Year Net Revenue of $149.7 Million and $566.8 Million – – Achieved Quarterly and Full-Year GAAP Net Income of $31.9 Million and $48.2 Million – – Delivered Record Quarterly and Full-Year Adjusted EBITDA of $104.2 Million and $367.0 Million – – Ended 2023 with Cash, Cash Equivalents and Marketable Securities of $310.5 Million – – Conference Call Scheduled for Today at 4:30 p.m. ET – ...

STOUGHTON, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report fourth quarter and full-year 2023 financial results after the market closes on Thursday, February 22, 2024. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Collegium Pharmaceutical (COLL) , which belongs to the Zacks Medical - Drugs industry.This specialty pharmaceutical company has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 5.67%.For the last reported quarter, Collegium Pharmaceutic ...

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Christopher James - Vice President, Investor Relations Joe Ciaffoni - President and CEO Colleen Tupper - Chief Financial Officer Scott Dreyer - Chief Commercial Officer Conference Call Participants David Amsellem - Piper Sandler Tim Lugo - William Blair Serge Belanger - Needham & Company Les Sulewski - Truist Securities Operator Greetings, and welcome to Collegium Pharmaceuticals Th ...

2022 Term Loan Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2023. The term "disclosure controls and procedures," as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in t ...

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Christopher James - Vice President-Investor Relations Joe Ciaffoni – President & Chief Executive Officer Colleen Tupper - Chief Financial Officer Scott Dreyer - Chief Commercial Officer Conference Call Participants David Amsellem - Piper Sandler Serge Belanger - Needham & Company Glen Santangelo - Jefferies Oren Livnat - H.C. Wainwright Les Sulewski - Truist Securities Operator Greeti ...

| --- | --- | --- | |-----------------------|-------|--------------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Q2'23 Earnings Report | | | | August 3, 2023 | | Nasdaq: COLL | Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipat ...

Table of Contents As of June 30, 2023, none of the above circumstances had occurred and as such, the 2026 Convertible Notes could not have been converted. (1) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice; and (2) the trading day immediately before the date the Company sends such notice. The 2026 Convertible Notes have customary default ...

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Christopher James - Vice President, Investor Relations Joe Ciaffoni - Chief Executive Officer Colleen Tupper - Chief Financial Officer Scott Dreyer - Chief Commercial Officer Conference Call Participants David Amsellem - Piper Sandler Tim Lugo - William Blair Brandon Folkes - Cantor Fitzgerald Serge Belanger - Needham & Company Greg Fraser - Truist Securities Glen Santangelo - Jefferies ...